MAXIM BITUNOV: Open Payments
NPI 1821430349 · PITTSFIELD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$894 in 17 payments from 6 companies in 2025. Trend: 2023 $204 · 2024 $299 · 2025 $894
Food & beverage: $894
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 5 | $330 |
| ABBVIE INC. | 8 | $182 |
| Neurocrine BioSciences, Inc. | 1 | $125 |
| Verona Pharma, Inc. | 1 | $124 |
| GlaxoSmithKline, LLC. | 1 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $64 |
Products named: KISUNLA, INGREZZA, Ohtuvayre, UBRELVY, ZEPBOUND, SHINGRIX, VRAYLAR, CAPLYTA.
Industry payments across MA — which companies pay providers there.
